{
    "2021-03-15": [
        [
            {
                "time": "",
                "original_text": "中国首个自主研发的门冬胰岛素30注射液生产在即 甘李药业加速国产替代",
                "features": {
                    "keywords": [
                        "门冬胰岛素",
                        "自主研发",
                        "甘李药业",
                        "国产替代"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "高瓴资本概念股普遍调整，泰格医药、甘李药业、凯莱英、金域医学领跌",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "概念股",
                        "调整",
                        "泰格医药",
                        "甘李药业",
                        "凯莱英",
                        "金域医学",
                        "领跌"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}